Expanded utilization of rituximab in paediatric cardiac transplant patients
| Autor: | Bethany L. Wisotzkey, Jennifer Carapellucci, Alfred Asante-Korang, Amy L. Kiskaddon, Katherine B. Landmesser |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Epstein-Barr Virus Infections medicine.medical_specialty Population Neutropenia Drug Administration Schedule hemic and lymphatic diseases Internal medicine medicine Humans Immunologic Factors Pharmacology (medical) education Retrospective Studies Pharmacology CD20 Purpura Thrombocytopenic Idiopathic education.field_of_study Dose-Response Relationship Drug biology business.industry Autoimmune Cytopenia Infant Newborn Infant Retrospective cohort study medicine.disease Thrombocytopenic purpura Transplantation biology.protein Heart Transplantation Female Rituximab Anemia Hemolytic Autoimmune business medicine.drug |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 46:762-766 |
| ISSN: | 1365-2710 0269-4727 |
| DOI: | 10.1111/jcpt.13346 |
| Popis: | WHAT IS KNOWN AND OBJECTIVE Epstein-Barr virus (EBV) viraemia and autoimmune cytopenias (AICs) are significant complications that occur following paediatric solid organ transplantation. A variety of treatment methods have been investigated but limited research has focused on the utilization of rituximab in paediatric cardiac transplant recipients for these indications. Rituximab is a monoclonal antibody that binds the CD20 antigen on the surface of B-type lymphocytes resulting in B-cell cytotoxicity. It is considered a second-line therapy for treatment of autoimmune cytopenias and EBV viraemia following adult solid organ transplant (SOT) and haematopoietic stem cell transplant (HSCT). However, data for its use in the paediatric population for treatment of autoimmune cytopenias are lacking. Dosing is based on adult studies, and the frequency and length of therapy associated with resolution of EVB viraemia and AICs in paediatric cardiac transplant recipients is unknown. The objective of this retrospective study was to describe the dosing and length of therapy of expanded off-label use of rituximab for the management of refractory EBV viraemia and AICs, specifically in paediatric cardiac transplant patients. METHODS A retrospective chart review was conducted evaluating children |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|